COVID-19 Public Health Laboratory Capacity and Capabilities
Weekly Data Report | Week 16 (July 27 - August 2, 2020)

Beginning April 13, 2020, the Association of Public Health Laboratories (APHL) has conducted a weekly survey of up to 100 state, local and territorial public health laboratories (PHLs) to collect the status of current and projected capability and capacity of laboratories to test for SARS-CoV-2, the virus that causes the Coronavirus Disease (COVID-19). Data from this survey is used to inform HHS, FEMA, CDC and other federal partners to support public health laboratory supply and reagent needs.

OVERALL TESTING CAPACITY
Current testing and supply demands (n=81)

- 325,120 specimens tested during the previous week (Data from CDC)
- 80% of PHLs able to meet their current testing demand
- 23% of PHLs that will run out of reagents or supplies within a week

SEROLOGY / ANTIBODY TESTING
Status of serological testing implementation (n=99)

- 35% of PHLs currently perform serological testing
- 42% of PHLs intend to perform serological testing
- 22% of PHLs testing not planned yet

HIGH THROUGHPUT TESTING PLATFORMS
Status of high throughput testing platforms* in the laboratory (n=99)

- 61% of PHLs have at least one high throughput platform
- 39% of PHLs do not have a high throughput platform

Number of high throughput platforms* per laboratory, of those with at least one (n=60)

- 57% of PHLs have one high throughput platform
- 23% have two
- 10% have three
- 5% have four
- 3% have five
- 2% have six

* High throughput platforms are automated equipment that can test many specimens at a time while minimizing the hands-on time required by laboratory staff. High throughput platforms currently in use are Hologic Panter, Hologic Panther Fusion, Abbott m200 and the BD Max.